Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe
Alkermes announced that its investigational orexin 2 receptor agonist, alixorexton, has received orphan drug designations from both the FDA and the European Commission. The FDA granted designation for the treatment of idiopathic hypersomnia (IH), while the European Commission granted it for narcolepsy. These designations unlock significant development incentives, including tax credits, fee waivers, and potential market exclusivity periods of seven years in the U.S. and up to ten years in Europe.
Key figures
- Drug Name
- alixorexton
- Phase Of Trial
- Phase 3
- Prevalence us ih
- 40,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.